X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
The Company intends to use the net proceeds to advance the development and commercialization of its product pipeline, including Anaphylm™ (epinephrine) Sublingual Film for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Anaphylm
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Leerink Partners
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 25, 2024
Details:
Neffy (epinephrine) is a nasal spray that acts as a adrenergic receptor agonist. It is being developed for the treatment of Type I allergies, including anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Neffy
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2024
Details:
The Company intends to use the net proceeds to advance the development and commercialization of its product pipeline, including Anaphylm™ (epinephrine) Sublingual Film for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Anaphylm
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Leerink Partners
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 19, 2024
Details:
Anaphylm (epinephrine) is a polymer matrix-based epinephrine prodrug candidate product. It is being evaluated for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Anaphylm
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2024
Details:
Neffy (epinephrine) is a nasal spray that acts as a adrenergic receptor agonist. It is being developed for the treatment of Type I allergies, including anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Neffy
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
Neffy (epinephrine) is a nasal spray that acts as a adrenergic receptor agonist. It is being developed for the treatment of Type I allergies, including anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Neffy
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
FMXIN002 (epinephrine) is an adrenergic receptor agonist small molecule drug candidate, which is currently being evaluated for the treatment of anaphylaxis via intranasal spray.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: FMXIN002
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
Anaphylm (epinephrine) is an adrenergic receptor agonist hormone drug candidate. It is being evaluated for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Anaphylm
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
Neffy (epinephrine) is a nonselective alpha- and beta-adrenergic receptor agonist. Through its action on alpha-adrenergic receptors, it reduces vasodilation and increases vascular permeability that occurs during anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Neffy
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2023
Details:
Neffy (epinephrine) is a nonselective alpha- and beta-adrenergic receptor agonist. Through its action on alpha-adrenergic receptors, it reduces vasodilation and increases vascular permeability that occurs during anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Neffy
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2023
Details:
Anaphylm (AQST-109) is a polymer matrix-based epinephrine prodrug candidate product administered as a sublingual film that is applied under the tongue for the rapid delivery of epinephrine for the treatment of severe allergy and anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Anaphylm
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
Details:
Anaphylm (AQST-109) is a polymer matrix-based epinephrine prodrug candidate product administered as a sublingual film that is applied under the tongue for the rapid delivery of epinephrine for the treatment of Severe allergy and anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Anaphylm
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
Neffy (epinephrine) is a nonselective alpha- and beta-adrenergic receptor agonist. Through its action on alpha-adrenergic receptors, it reduces vasodilation and increases vascular permeability that occurs during anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Neffy
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2023
Details:
Neffy (epinephrine) is a nonselective alpha- and beta-adrenergic receptor agonist. Through its action on alpha-adrenergic receptors, it reduces vasodilation and increases vascular permeability that occurs during anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Neffy
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Details:
Anaphylm (epinephrine, previously known as AQST-109) acts on alpha-1 receptors, induces increased vascular smooth muscle contraction, pupillary dilator muscle contraction, and intestinal sphincter muscle contraction.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Anaphylm
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2023
Details:
Neffy (epinephrine) is a nonselective alpha- and beta-adrenergic receptor agonist. Through its action on alpha-adrenergic receptors, it reduces vasodilation and increases vascular permeability that occurs during anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Neffy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
Details:
Epinephrine is a nonselective alpha- and beta-adrenergic receptor agonist. Through its action on alpha-adrenergic receptors, it reduces vasodilation and increases vascular permeability that occurs during anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Epinephrine-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2023
Details:
Utuly (epinephrine) is a nonselective alpha- and beta-adrenergic receptor agonist. Through its action on alpha-adrenergic receptors, it reduces vasodilation and increases vascular permeability that occurs during anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Utuly
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2023
Details:
Neffy (epinephrine) is a nonselective alpha- and beta-adrenergic receptor agonist. Through its action on alpha-adrenergic receptors, it reduces vasodilation and increases vascular permeability that occurs during anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Neffy
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2023
Details:
Under the agreement, ARS Pharmaceuticals Reacquires commercial rights to neffy (ARS-1) in the European region. Neffy is an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions leading to anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Neffy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: ARS Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 22, 2023
Details:
AQST-109 is a polymer matrix-based epinephrine prodrug administered as a sublingual film that is applied under the tongue for the rapid delivery of epinephrine.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: AQST-109
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2022
Details:
Data from the EPI-15 and EPI-16 clinical trials demonstrated that neffy delivered consistent epinephrine levels to attain pharmacokinetic (PK) profile in range of approved intra-muscular (IM) injection products’ PK under normal and rhinitis conditions.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Neffy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2022
Details:
AQST-109 is a polymer matrix-based epinephrine prodrug administered as a sublingual film that is applied under the tongue for the rapid delivery of epinephrine.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: AQST-109
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2022
Details:
ARS has designed and developed neffy® to provide injection-like absorption of epinephrine, in a small, easy-to-carry, easy-to-use, rapidly administered, and reliable nasal spray device for the treatment of Type I severe allergic reactions , including anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Neffy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: ARS Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger November 08, 2022
Details:
Neffy® (epinephrine nasal spray) has potential to be the first non-injectable medicine indicated to treat allergic reactions (type I) including anaphylaxis in the U.S., if approved.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Neffy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
Details:
OX640 (adrenaline) formulations showed concentration dependent effects on heart rate and blood pressure, a pharmacological response relevant for the treatment of allergic reactions.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: OX640
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
AQST-109 (epinephrine) is a polymer matrix-based epinephrine prodrug administered as a sublingual film that is applied under the tongue for the rapid delivery of epinephrine. The product weighs less than an ounce, and begins to dissolve on contact.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: AQST-109
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
AQST-109 (epinephrine) is polymer matrix-based epinephrine prodrug administered as a sublingual film that is applied under the tongue for rapid delivery of epinephrine. AQST-109 repeat dosing provided significantly higher drug plasma concentrations with a Tmax of 8 minutes.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: AQST-109
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2022
Details:
Utuly, an epinephrine nasal spray, for the treatment of anaphylaxis. It is designed to provide patients with a life-saving treatment that is needle free, fits in a pocket, is easy to use, and complies with practice parameters.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Utuly
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
OX640 is nasal adrenaline rescue medication based on the amorphOX® drug delivery platform is a unique and innovative new product to be used for the emergency treatment of allergic reactions.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: OX640
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2022
Details:
Epinephrine injection USP, 1 mg/10mL (0.1 mg/mL) Single Dose Pre-Filled Syringe is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.
Lead Product(s): Epinephrine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2022
Details:
Under the Agreement, Valeo will be responsible for all commercial and medical activities for ALLERJECT (epinephrine) in Canada for an initial 10 years period.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Allerject
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: KALEO INC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 02, 2022
Details:
ARS designed neffy to provide injection-like absorption of epinephrine, in a small, easy-to-carry, easy-to-use, and reliable nasal spray device. With its needle-free administration, neffy may help eliminate the anxiety and hesitation associated with using an autoinjector.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Neffy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Silverback Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger July 21, 2022
Details:
Study results for the sublingual administration of AQST-109 epinephrine oral film after consuming a peanut butter sandwich demonstrates consistent Tmax of 12 minutes.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: AQST-109
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2022
Details:
Stability data generated so far for OX640 (adrenaline) strongly indicates the potential for an adrenaline product with significantly improved stability versus today's injection products, both in terms of allowed storage temperatures as well as shelf-life.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: OX640
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2022
Details:
The median time to maximum concentration (Tmax) was observed to be 12 minutes for AQST-109 compared to 50 minutes for the epinephrine 0.3mg intra-muscular (IM) injection from Part 2 of the EPIPHAST study.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: AQST-109
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2022
Details:
Proceeds will include attaining and maximizing profitability and continuing licensing activities. Company remain focused on the FDA’s review of Libervant and the ongoing clinical development of oral epinephrine oral film candidate, AQST-109.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: AQST-109
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $8.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 08, 2022
Details:
Juno intends to use these proceeds to expand its complex and high-value generic and biosimilar portfolio including Adrenaline Aguettant. Signet will further enhance Juno’s already strong growth profile given their extensive experience in pharma, and specifically with generics.
Lead Product(s): Epinephrine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Adrenaline Aguettant-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Signet
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing February 24, 2022
Details:
Windgap and its manufacturing partners are commercializing its ANDI® wet/dry autoinjector platforms. The first product using this platform will be epinephrine for the treatment of anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Taiwania Capital
Deal Size: $17.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 07, 2021
Details:
The Company will use the funds to advance Neffy™ through approval, to support initial launch activities, and to evaluate Neffy in clinical studies for additional indications.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Neffy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing August 31, 2021
Details:
Kaléo has completed negotiations with the pan Canadian Pharmaceutical Alliance (pCPA) for a Letter of Intent regarding ALLERJECT® (epinephrine injection, USP) auto-injector for the treatment of serious allergic reactions.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Allerject
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: pan Canadian Pharmaceutical Alliance
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 10, 2020
Details:
The FDA has granted the Aquestive's AQST-108 Fast Track designation, "first of its kind" oral sublingual film formulation that delivers systemic epinephrine to treat allergic reactions, including anaphylaxis, using the proprietary Aquestive PharmFilm ® technologies.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: AQST-108
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2020
Details:
Proceeds from the financing will be used to fund the remaining development and regulatory approval activities, and pre-launch commercialization program for BRYN-NDS1C, Bryn's bi-dose epinephrine nasal spray.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: BRYN-NDS1C
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $26.0 million Upfront Cash: Undisclosed
Deal Type: Financing August 04, 2020
Details:
Patent approval covers fast-acting decreased dosage level for intranasal administration for type 1 allergic reaction.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: ARS-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2020
Details:
Aquestive plans to initiate its PK clinical trials of AQST-108 in a crossover study to compare the pharmacokinetics and pharmacodynamics of epinephrine administered as sublingual film to that of epinephrine administered as an injection.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: AQST-108
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2020
Details:
The preclinical results described in the publications were used to support the advancement of BRYN-NDS1C into the human clinical trial program currently underway.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2020
Details:
For the emergency drug epinephrine from TEVA, Schreiner MediPharm developed an Autoinjector-Label with special protection against abrasion.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Teva Pharmaceutical Industries
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 08, 2020
Details:
Adamis and Sandoz have reached an agreement allowing for the mutually agreed return to Adamis of SYMJEPI products' marketing, promotion and distribution rights and the termination of the deal.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Symjepi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination May 11, 2020
Details:
US WorldMeds obtained U.S. rights to commercialize and distribute the SYMJEPI products, upon the termination of Sandoz’ commercial rights, and ZIMHI.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: US WorldMeds
Deal Size: $26.0 million Upfront Cash: Undisclosed
Deal Type: Agreement May 11, 2020
Details:
The presentation will highlight promising results for ARS Pharmaceuticals' lead asset, ARS-1 which results in bioequivalent exposure to epinephrine injection given once and twice.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
